Advertisement
Advertisement
U.S. markets close in 5 hours 20 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Forte Biosciences, Inc. (FBRX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.2100+0.0200 (+1.68%)
As of 10:22AM EDT. Market open.
Advertisement

Forte Biosciences, Inc.

3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
United States
310 618 6994
https://www.fortebiorx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul A. Wagner Ph.D.CEO & Chairman752.5kN/A1970
Mr. Antony A. Riley CPAChief Financial Officer456kN/A1967
Dr. Hubert C. Chen M.D.Pres & Chief Scientific OfficerN/AN/A1969
Mr. Christopher RoenfeldtChief Operating OfficerN/AN/AN/A
Mr. Steven RuhlChief Technical OfficerN/AN/A1957
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Corporate Governance

Forte Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement